DFTX Company Profile and Key Details

Definium Therapeutics, Inc. (NASDAQ:DFTX) closed at $17.62 USD, gaining $0.17 (0.97%) from the previous close of $17.45. The stock is currently mid-range between its 52-week high and low $12.88 and $18.70. With a market capitalization of about $1.71 billion, Definium Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~2.62). Key stats such as the average daily volume over the past year has been around 2.53 million shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Definium Therapeutics, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Robert Barrow, the company employs approximately 74 people and listed since January 06, 2026. Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Definium Therapeutics, Inc. generated EPS of -$1.97 over the past year. Five-year average earnings growth is 12.11%. Wall Street analysts project EPS growth of -0.05% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $25.00. The high target offers 104.31% upside. The low target suggests 41.88% downside. The mean target is $30.33. This offers 72.13% upside. Definium Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 50.0%. The prior quarter beat by 31.58%. Over the last six quarters, Apple has recorded several small beats. These include 24.24% in March 06, 2025.

Definium Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.36. This means the shares are trading above this model’s fair value.

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares are up 25.32% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Definium Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.95. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $30.33, suggesting 72.13% upside. Our AI forecast model points to short-term weakness (-0.96% over two weeks), a medium-term rise (28.89% over three months), and a longer-term gain (164.7% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Definium Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.96%, with price expected at $17.45 by March 11, 2026, within a range of $16.90 to $18.03 3-Month Outlook: Projected rise of 28.89%, reaching $22.71 by May 26, 2026, with a range of $22.63 to $22.78. 1-Year Outlook: Projected gain of 164.7%, with price at $46.64 by February 25, 2027, within a range of $46.48 to $46.79.

Definium Therapeutics, Inc. trades at a P/E ratio of -8.95, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 11.52 reflecting a rich premium to book value. The P/FCF stands at -14.95, also above market averages. Compared to sector medians, Definium Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.